Buprenorphine 7 Day Matrix Patch 5µg/h, 10µg/h, 15µg/h, 20µg/h Moving from BuTrans 5,10,15or 20µg/h to Butec..


A like for like switch..


Butec sits in Category C of the drug tariff.


Prescribing Butec by brand is the only way to ensure patients receive a like for like switch while delivering drug cost savings to the NHS.


For further information and latest pricing please contact Qdem enquiries on: 01223 426929


Or contact your local account manager at: http://www.qdem.co.uk/hcp/team/


Butec patches contain an opioid analgesic. Butec® 5 µg/h, 10 µg/h, 15 µg/h and 20 µg/h Transdermal Patch PRESCRIBING INFORMATION United KingdomPLEASE READ THE SUMMARY OF PRODUCT CHARACTERISTICS BEFORE PRESCRIBING.PRESENTATION Butec 5 µg/h, 10 µg/h, 15 µg/h, 20 µg/h. Transdermal beige patches containing buprenorphine. INDICATIONS Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Butec is not suitable for the treatment of acute pain. DOSAGE AND ADMINISTRATION Butec should be administered every 7th day. Elderly and adults over 18 years only: Use the 5 μg/h patch for at least the first 3 days of treatment, before increasing the dose if necessary. Short-acting supplemental analgesics may be required during titration until analgesic efficacy is attained. Do not use more than two patches at a time, up to a maximum dose of 40 µg/h. CONTRA-INDICATIONS Known buprenorphine or excipient hypersensitivity, opioid-dependent patients, narcotic withdrawal treatment, respiratory depression, use of monoamine oxidase inhibitors (MAOIs) within the past 2 weeks, myasthenia gravis, delirium tremens. PRECAUTIONS AND WARNINGS Acute alcohol intoxication, head injury, shock, reduced consciousness of uncertain origin, intracranial lesions or increased intracranial pressure, severe hepatic impairment, history of drug abuse, alcohol abuse, serious mental illness or seizure disorder. Not recommended immediately postoperatively or for situations characterised by a narrow therapeutic index or for rapidly varying analgesic requirements. Chronic use


of buprenorphine may lead to physical dependence and a withdrawal syndrome may occur. May affect ability to drive and use machinery. INTERACTIONS MAOIs, CNS depressants (e.g. benzodiazepines, opioid derivatives, antidepressants, sedatives, alcohol, anxiolytics, neuroleptics, clonidine). CYP 3A4 inhibitors and inducers, products reducing hepatic blood flow (e.g. halothane). PREGNANCY AND LACTATION Butec should not be used during pregnancy or in women of childbearing potential who are not using effective contraception. The use of Butec during lactation should be avoided. SIDE-EFFECTS Very common (≥1/10) and common (≥1/100, <1/10) side- effects are anorexia, confusion, depression, insomnia, nervousness, anxiety, headache, dizziness, somnolence, tremor, dyspnoea, constipation, nausea, vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth, pruritus, erythema, rash, sweating, exanthema, muscular weakness, application site reaction, tiredness, asthenic conditions, peripheral oedema.Uncommon (< 1/100) but potentially serious side-effects are hypersensitivity, anaphylactic/anaphylactoid reaction, affect lability, restlessness, agitation, euphoric mood, hallucinations, libido decreased, aggression, psychotic disorder, drug dependence, mood swings, depersonalisation, sedation, dysarthria, migraine, syncope, paraesthesia, balance disorder, speech disorder, convulsions, blurred vision, visual disturbance, eyelid oedema, vertigo, palpitations, tachycardia, angina pectoris, hypotension, circulatory collapse, hypertension, orthostatic hypotension, wheezing, respiratory depression, respiratory failure,


asthma aggravated, hyperventilation, dysphagia, ileus, diverticulitis, biliary colic, urticaria, dermatitis contact, face oedema, urinary retention, erectile dysfunction, sexual dysfunction, oedema, drug withdrawal syndrome (including neonatal), chest pain, alanine aminotransferase increased, accidental injury, fall. Please consult the SPC for details of other side-effects. LEGAL CATEGORY CD (Sch3) POM PACKAGE QUANTITIES AND PRICE 4 individually sealed patches: 5 µg/h transdermal patch £7.92, 10 µg/h transdermal patch £14.20, 15 µg/h transdermal patch £22.12, 20 µg/h transdermal patch £25.86. Marketing Authorisation numbers PL 40431/0024 – 0027. MARKETING AUTHORISATION HOLDER Qdem Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge, CB4 0AB, United Kingdom. Tel: 01223 426929. For medical information enquiries, please contact medicalinformationukQdem@ qdem.co.uk. DATE EFFECTIVE: February 2017. ® Butec and QDEM are registered trade marks. © 2013 Qdem Pharmaceuticals Limited.


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/ yellowcard. Adverse events should also be reported to Qdem Pharmaceuticals Limited on 01223 426929.


PI CODE: UK/QDEM-16010(6) PI APPROVED: January 2017


www.qdem.co.uk


® Butec and QDEM are registered trade marks. © 2013 Qdem Pharmaceuticals Limited. Date of preparation: January 2018 UK/QDEM-16023a(2)


ButecPracticeJournal_16023a(2).indd 1


10/01/2018 16:14


55% Saving when Butec Prescribed


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64